Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,413 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active capsule Clear all
Completed Phase 2 Interventional

A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

NCT00367887
View directory record Official record
Conditions
Hepatitis C
Interventions
Peg-Intron, REBETOL, HCV 796
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Anaheim, California • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome

NCT00344721
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Omega-3 fatty acid supplement, Placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 24, 2026, 11:15 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136
View directory record Official record
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 24, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

NCT05044234
View directory record Official record
Conditions
Psoriasis
Interventions
Cedirogant, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Pain Associated With Fibromyalgia

NCT02187471
View directory record Official record
Conditions
Pain Associated With Fibromyalgia
Interventions
DS-5565, Pregabalin, Placebo tablet, Placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
91
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 24, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional Results available

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

NCT04517864
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Huntington Beach, California • Irvine, California • Boca Raton, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of LasoperinTM on Cognitive Function in Healthy Adults

NCT05994391
View directory record Official record
Conditions
Cognitive Impairment, Cognitive Decline, Cognition Disorders in Old Age, Well-Being, Psychological, Inflammation, Cognitive Fun
Interventions
LasoperinTM, Placeo
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
30 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 24, 2026, 11:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

NCT04490915
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Crinecerfont, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

NCT00622284
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI 1356 5mg, Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, BI 1356, Glimepiride
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
23
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 1 Interventional

Phase 1 Safety Testing of SAR405838

NCT01636479
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
SAR405838
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

NCT05063994
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort, Cortef, Placebo
Drug · Other
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 11:15 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

NCT06891066
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
ISL, ULO, BIC/FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 2 Interventional

8 Week Multi-site Study of MYDAYIS® for Bipolar Depression

NCT04235686
View directory record Official record
Conditions
Bipolar Depression
Interventions
Mydayis Extended-Release Capsule, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

NCT03084796
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
CHF 5259, Placebo, Tiotropium Bromide 18 µg Inhalation Capsule
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
112
States / cities
Birmingham, Alabama • Dothan, Alabama • Montgomery, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)

NCT05776862
View directory record Official record
Conditions
Spinal Cord Injuries, Tetraplegia, Paraplegia, Muscle Loss, Atrophy, Muscular, Insulin Resistance
Interventions
Ursolic Acid, Strength Training
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combined Medication for Improved Analgesia in Superficial Pain

NCT02194088
View directory record Official record
Conditions
Pain
Interventions
Diclofenac and Atropine combination drug, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 2 Interventional

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

NCT03527472
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Memantine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Cleveland, Ohio • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 3 Interventional

THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

NCT00578695
View directory record Official record
Conditions
Hyponatremia
Interventions
lixivaptan, Placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Bakersfield, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 24, 2026, 11:15 AM EDT
Recruiting Phase 3 Interventional

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib, Active Comparator, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

NCT01147666
View directory record Official record
Conditions
End Stage Renal Disease, Anemia
Interventions
Roxadustat, Epoetin Alfa, Placebo
Drug · Other
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 3 Interventional

TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

NCT00258557
View directory record Official record
Conditions
HIV
Interventions
LPV/RTV, TMC-114/RTV
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 24, 2026, 11:15 AM EDT
Terminated Phase 3 Interventional

Chemoprevention of Colorectal Adenomas

NCT00486512
View directory record Official record
Conditions
Adenomatous Polyps
Interventions
0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), Colonoscopy
Drug · Procedure
Lead sponsor
Colotech A/S
Industry
Eligibility
40 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Huntsville, Alabama • San Diego, California • Clearwater, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 1 Interventional

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

NCT06399757
View directory record Official record
Conditions
Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer
Interventions
APL-5125
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Duarte, California • Irvine, California • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 24, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Study of SBP-9330 in Healthy Subjects

NCT04948827
View directory record Official record
Conditions
Smoking Cessation
Interventions
SBP-9330, Placebo
Drug
Lead sponsor
Camino Pharma, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 24, 2026, 11:15 AM EDT